Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) Operating Expenses (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Operating Expenses for 4 consecutive years, with $36.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Expenses rose 1.56% to $36.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $147.2 million, a 0.04% change, with the full-year FY2024 number at $144.7 million, down 2.73% from a year prior.
  • Operating Expenses was $36.1 million for Q3 2025 at Century Therapeutics, up from $34.7 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $44.0 million in Q4 2023 to a low of $32.2 million in Q1 2024.
  • A 4-year average of $35.9 million and a median of $35.2 million in 2023 define the central range for Operating Expenses.
  • Biggest YoY gain for Operating Expenses was 30.16% in 2023; the steepest drop was 12.19% in 2023.
  • Century Therapeutics' Operating Expenses stood at $33.8 million in 2022, then skyrocketed by 30.16% to $44.0 million in 2023, then dropped by 5.84% to $41.5 million in 2024, then decreased by 12.85% to $36.1 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Operating Expenses are $36.1 million (Q3 2025), $34.7 million (Q2 2025), and $35.0 million (Q1 2025).